Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells

rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia

(2011) X. Ge et al.   CLINICAL CANCER RESEARCH

Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients

(2011) R. Stephanie Huang et al.   CLINICAL CANCER RESEARCH

Genomic Profiling in CEPH Cell Lines Distinguishes between the Camptothecins and Indenoisoquinolines

(2011) V. G. Watson et al.   MOLECULAR CANCER THERAPEUTICS

Pharmacogenomic characterization of US FDA-approved cytotoxic drugs

(2011) Eric J Peters et al.   PHARMACOGENOMICS

Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance

(2010) C. Henry et al.   BLOOD

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

(2010) S. A. Beers et al.   BLOOD

U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab

(2010) S. J. Lemery et al.   CLINICAL CANCER RESEARCH

Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies

(2010) Bruce D. Cheson   JOURNAL OF CLINICAL ONCOLOGY

Evolution of anti- CD20 monoclonal antibody therapeutics in oncology

(2010) Ezogelin Oflazoglu et al.   mAbs

Escape mechanisms from antibody therapy to lymphoma cells: Downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation

(2009) Takumi Sugimoto et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma

(2009) Y. Terui et al.   CLINICAL CANCER RESEARCH

Anti-CD20 monoclonal antibodies: historical and future perspectives

(2009) S. H. Lim et al.   HAEMATOLOGICA

Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX

(2009) A. W. Pawluczkowycz et al.   JOURNAL OF IMMUNOLOGY

A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma

(2008) Arturo Molina   Annual Review of Medicine

Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity

(2008) C. M. Hartford et al.   BLOOD

Development of Novel Tetravalent Anti-CD20 Antibodies with Potent Antitumor Activity

(2008) B. Li et al.   CANCER RESEARCH

A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma

(2008) E. Racila et al.   CLINICAL CANCER RESEARCH

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

(2008) M. S. Czuczman et al.   CLINICAL CANCER RESEARCH

A review of the current use of rituximab in autoimmune diseases

(2008) Hakan M. Gürcan et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

CD20 Homo-oligomers Physically Associate with the B Cell Antigen Receptor

(2008) Maria J. Polyak et al.   JOURNAL OF BIOLOGICAL CHEMISTRY